• Canagliflozin Alters Mitochondrial Structure in Diabetic Kid

  2026-05-14

  This study demonstrates that canagliflozin, an SGLT2 inhibitor, improves mitochondrial structure and bioenergetics in proximal tubular cells of hypertensive–diabetic mice, with pronounced effects in males. These findings highlight mitochondrial remodeling as a potential mechanism for the kidney-protective actions of SGLT2 inhibition, informing future diabetes and renal research.

• Aconitase Activity Colorimetric Assay Kit: Optimizing Oxidat

  2026-05-14

  Harness the precision and speed of the Aconitase Activity Colorimetric Assay Kit to quantify mitochondrial aconitase activity and oxidative stress in high-throughput workflows. This guide delivers actionable protocol enhancements, troubleshooting insights, and innovative applications for immunometabolic research, making it indispensable for studies where TCA cycle enzyme dynamics matter most.

• EdU Imaging Kits (Cy5): Unveiling Cell Proliferation in Vasc

  2026-05-13

  Explore how EdU Imaging Kits (Cy5) empower sensitive detection of cell proliferation, with unique insights into vascular remodeling and disease mechanisms. Discover workflow guidance and scientific depth beyond conventional EdU assay coverage.

• EPI-001 (SKU B6041): Reliable AR N-Terminal Inhibition in On

  2026-05-13

  This article provides a scenario-driven, evidence-based overview of EPI-001 (SKU B6041), an androgen receptor N-terminal domain inhibitor for cell viability and proliferation studies in AR-driven cancers. Drawing on recent literature and validated protocols, it addresses practical lab challenges, vendor selection, and data interpretation, guiding researchers toward reproducible outcomes using EPI-001.

• Targeting Lin28B/Let-7/PBK Axis in TNBC: Ponicidin’s Mechani

  2026-05-12

  This study elucidates the role of the Lin28B/Let-7/PBK axis in triple-negative breast cancer (TNBC) and identifies ponicidin as a dual-mode Lin28B inhibitor. Through integrated computational, molecular, and in vivo analyses, the research demonstrates ponicidin’s efficacy in suppressing TNBC progression and highlights new avenues for targeted therapy.

• LY2228820: p38 MAP Kinase Inhibitor in Anti-Inflammatory Res

  2026-05-12

  LY2228820 is a potent, selective p38 MAP kinase inhibitor that empowers advanced anti-inflammatory and cancer research through precise pathway modulation. This article delivers actionable workflows, troubleshooting strategies, and contextualizes new innovations from airway stent technology to experimental assay design.

• Cy3 NHS Ester (Non-Sulfonated): Technical Guide for Biomolec

  2026-05-11

  Cy3 NHS ester (non-sulfonated) offers reliable fluorescent labeling of proteins, peptides, and oligonucleotides where organic co-solvent compatibility is assured. It is best suited for workflows requiring orange emission (excitation 555 nm, emission 570 nm) and is not recommended for aqueous-only protocols or long-term dye solution storage.

• EdU Imaging Kits (Cy5): Redefining S-Phase Proliferation Ins

  2026-05-11

  This article delivers critical mechanistic context and strategic guidance for translational researchers leveraging EdU Imaging Kits (Cy5) in cell proliferation, genotoxicity, and pharmacodynamic studies. It integrates recent advances in HB biology—including the nNOS-TCOF1-KRAS axis—as an urgent rationale for robust S-phase DNA synthesis measurement. By dissecting the biological imperative, validating performance, and mapping translational value, this thought piece moves beyond traditional product overviews to set new standards for experimental rigor and impact.

• Fluorescein TSA Fluorescence System Kit: Deep Dive on Neural

  2026-05-10

  Explore how the Fluorescein TSA Fluorescence System Kit enables ultrasensitive neural pathway mapping and signal amplification in fibrosis research. This in-depth analysis highlights the scientific mechanisms, protocol optimization, and insights from recent renal fibrosis literature.

• Dual-Action Inhibitors Accelerate p38α MAPK Dephosphorylatio

  2026-05-09

  This study unveils that certain kinase inhibitors not only block p38α MAP kinase activity but also enhance its dephosphorylation by stabilizing a phosphatase-accessible conformation. These findings suggest new strategies for achieving specificity and efficacy in kinase inhibition, with direct implications for anti-inflammatory and cancer research.

• Mechanistic Advances in Mouse Genotyping: Strategic Pathways

  2026-05-08

  This article blends mechanistic insight into DNA extraction from mouse tail tissue with strategic guidance for translational researchers. It demonstrates how APExBIO's lysis buffer, as a rapid genotyping kit component, underpins robust, reproducible workflows in preclinical genetics. Integrating recent findings on tumor microenvironment signatures in colorectal cancer, we explore how high-fidelity genotyping enables the next generation of translational oncology research. Readers will gain actionable recommendations, protocol parameters, and a roadmap for leveraging genomic DNA extraction innovations in both basic and applied contexts.

• LNP-NamiRNA Dual Pathway Suppression of Pancreatic Cancer Pr

  2026-05-08

  Yu et al. (2025) demonstrate that lipid nanoparticle (LNP)-delivered mir-200c can inhibit pancreatic cancer cell proliferation and migration via dual mechanisms: transcriptional activation of PTPN6 and post-transcriptional repression of CDH17. These findings reveal a novel regulatory paradigm for nuclear activating miRNAs (NamiRNAs) and suggest new therapeutic strategies for difficult-to-treat malignancies.

• CAFs-Derived Fatty Acids Drive Oral Cancer via Lipid Rafts

  2026-05-07

  This study reveals that cancer-associated fibroblasts (CAFs) in the tumor microenvironment secrete free fatty acids (FFAs) that are taken up by oral squamous cell carcinoma (OSCC) cells to promote lipid raft formation and activate oncogenic PI3K/AKT signaling. The findings suggest that targeting the CAF–lipid raft–signaling axis could be a promising therapeutic strategy for oral cancer progression.

• Ribonuclease R (20 U/μL): Precision Tool for Circular RNA En

  2026-05-07

  Ribonuclease R (RNase R) (20 U/μL) enables selective linear RNA degradation, facilitating robust circular RNA enrichment and in-depth RNA structure analysis. APExBIO’s RNase R is validated for stability and performance in workflows requiring high specificity for linear RNA digestion. This article details evidence, protocol parameters, and critical boundaries for scientific use.

• LY2228820: Mechanistic Insights and Assay Guidance for p38 M

  2026-05-06

  Explore the advanced mechanistic basis and assay optimization strategies for LY2228820, a leading p38 MAP kinase inhibitor. Discover how conformational dynamics and dual-action inhibition shape its research applications.

16210 records 1/1081 page Next 12345 下5页 Last page